Moldova - rumensk - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

ncpc international corp. - ceftazidimum - pulbere pentru soluţie injectabilă/perfuzabilă - 2 g

Moldova - rumensk - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

ncpc international corp. - ceftazidimum - pulbere pentru soluţie injectabilă/perfuzabilă - 0,5 g

Moldova - rumensk - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

ncpc international corp. - ceftazidimum - pulbere pentru soluţie injectabilă/perfuzabilă - 1 g

Den europeiske union - rumensk - EMA (European Medicines Agency)

ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - agenți antineoplazici - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.

Den europeiske union - rumensk - EMA (European Medicines Agency)

mylan pharmaceuticals limited - darunavir - infecții cu hiv - antivirale pentru uz sistemic - darunavir, co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv-1) infection (see section 4. darunavir mylan 75 mg, 150 mg, 300 mg and 600 mg tablets may be used to provide suitable dose regimens (see section 4. 2):pentru tratamentul infecției cu hiv-1 în tratament antiretroviral (art)-adult cu experiență de pacienți, inclusiv cei care au fost extrem de pre-tratate. pentru tratamentul infecției cu hiv-1 la pacienții copii și adolescenți începând cu vârsta de 3 ani și de cel puțin 15 kg greutate corporala. În decizia de a iniția tratamentul cu darunavir, administrat concomitent cu o doză mică de ritonavir, trebuie acordată o atenție deosebită la tratament istoria individuală a fiecărui pacient și modele de mutații asociate cu diferiți agenți. genotypic or phenotypic testing (when available) and treatment history should guide the use of darunavir (see sections 4. 2, 4. 4 și 5. darunavir, administrat concomitent cu o doză mică de ritonavir, este indicat, în asociere cu alte medicamente antiretrovirale pentru tratamentul pacienților infectați cu virusul imunodeficienței umane (hiv-1) infecție.  darunavir co-administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv-1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg) (see section 4.  darunavir mylan 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv-1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are: antiretroviral therapy (art)-naïve (see section 4.  art-experienced with no darunavir resistance associated mutations (drv-rams) and who have plasma hiv-1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 10⁶/l. În decizia de a iniția tratamentul cu darunavir în astfel de artĂ cu pacienți, genotipice de testare ar trebui să ghideze utilizarea de darunavir (a se vedea secțiunile 4. 2, 4. 3, 4. 4 și 5.

Den europeiske union - rumensk - EMA (European Medicines Agency)

ferring pharmaceuticals a/s - degarelix - prostate neoplasme - terapia endocrină - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Den europeiske union - rumensk - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin - diabetul zaharat, tip 2 - medicamente utilizate în diabet - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Den europeiske union - rumensk - EMA (European Medicines Agency)

pharmathen s.a. - acidul ibandronic - hypercalcemia; fractures, bone; neoplasm metastasis; breast neoplasms - medicamente pentru tratamentul bolilor osoase - concentrate for solution for infusion prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases. tratamentul hipercalcemiei induse de tumori cu sau fără metastaze. film-coated tablets prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.

Den europeiske union - rumensk - EMA (European Medicines Agency)

intervet international bv - orbifloxacin, furoat de mometazonă, posaconazol - auriculare- - câini - tratamentul otitei externe acute și exacerbări acute ale otitei externe recurente, asociate cu bacterii sensibile la orbifloxacin și fungi sensibili la posaconazol, în special malassezia pachydermatis.

Den europeiske union - rumensk - EMA (European Medicines Agency)

janssen-cilag international nv - canagliflozin - diabetul zaharat, tip 2 - medicamente utilizate în diabet - invokana is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 și 5.